Other function: monoclonal antibody targeting cancer stem cells
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261201400029C
- Awardee
-
Caerus Discovery, LLC UEI NMWYZJVYEFK9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $224,475
Award facts
- Opportunity
-
- N43CO4100527 Solicitation number
- Contract value 100% obligated
- $224,475.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 27 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Nokesville, VA 20181, USA
Award details come from SAM.gov/FPDS.
About this award
This is a Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Caerus Discovery, LLC, a Woman-Owned Small Business. The contract is valued at $224,475.00 and has a completion date of June 11, 2015. The contract is for the delivery of a monoclonal antibody targeting cancer stem cells. No set-aside was used for this award. The place of performance is Nokesville, Virginia.
Quick answers
Who was awarded contract HHSN261201400029C?
HHSN261201400029C was awarded to Caerus Discovery, LLC by National Cancer Institute (National Institutes of Health) on September 12, 2014.
How much is contract HHSN261201400029C worth?
The government has obligated $224,475 on HHSN261201400029C.
Was contract HHSN261201400029C competed?
The extent of competition for HHSN261201400029C was full and open competition. The government received 27 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award